Avrobio Inc (AVRO)
1.48
+0.04
(+2.78%)
USD |
NASDAQ |
May 31, 16:00
1.48
0.00 (0.00%)
After-Hours: 20:00
Avrobio Cash from Financing (Quarterly): 0.03M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 0.03M |
December 31, 2023 | 0.059M |
September 30, 2023 | 0.178M |
June 30, 2023 | -16.32M |
March 31, 2023 | 0.055M |
December 31, 2022 | 0.059M |
September 30, 2022 | 0.06M |
June 30, 2022 | 0.001M |
March 31, 2022 | 0.142M |
December 31, 2021 | 14.94M |
September 30, 2021 | 0.022M |
June 30, 2021 | 14.60M |
March 31, 2021 | 0.799M |
December 31, 2020 | 70.70M |
September 30, 2020 | 0.06M |
Date | Value |
---|---|
June 30, 2020 | 8.191M |
March 31, 2020 | 93.66M |
December 31, 2019 | 0.03M |
September 30, 2019 | 129.47M |
June 30, 2019 | 0.238M |
March 31, 2019 | 0.252M |
December 31, 2018 | -0.139M |
September 30, 2018 | -3.255M |
June 30, 2018 | 105.47M |
March 31, 2018 | 58.21M |
December 31, 2017 | 13.97M |
September 30, 2017 | -0.032M |
June 30, 2017 | -0.051M |
March 31, 2017 | 3.487M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-16.32M
Minimum
Jun 2023
129.47M
Maximum
Sep 2019
15.85M
Average
0.101M
Median
Cash from Financing (Quarterly) Benchmarks
AIM ImmunoTech Inc | 2.829M |
Perspective Therapeutics Inc | 166.33M |
Protalix BioTherapeutics Inc | 0.00 |
Electromed Inc | 0.056M |
Armata Pharmaceuticals Inc | 34.93M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -7.569M |
Free Cash Flow | -50.48M |
Free Cash Flow Per Share (Quarterly) | -0.169 |
Free Cash Flow Yield | -76.39% |